المؤلفون: Jun Liang (251318), Jason R. Zbieg (1892965), Robert A. Blake (8974823), Jae H. Chang (1429789), Stephen Daly (2430460), Antonio G. DiPasquale (1274730), Lori S. Friedman (166879), Thomas Gelzleichter (11113391), Matthew Gill (589302), Jennifer M. Giltnane (11113394), Simon Goodacre (1577413), Jane Guan (166826), Steven J. Hartman (10157036), Ellen Rei Ingalla (8908757), Lorn Kategaya (11113397), James R. Kiefer (1443889), Tracy Kleinheinz (1845637), Sharada S. Labadie (1833826), Tommy Lai (2572615), Jun Li (6494), Jiangpeng Liao (1947631), Zhiguo Liu (594653), Vidhi Mody (8908760), Neville McLean (2128303), Ciara Metcalfe (8908763), Michelle A. Nannini (11113400), Jason Oeh (1845505), Martin G. O’Rourke (11113403), Daniel F. Ortwine (1600621), Yingqing Ran (2100610), Nicholas C. Ray (3064926), Fabien Roussel (3030714), Amy Sambrone (1551289), Deepak Sampath (640340), Leah K. Schutt (11113406), Maia Vinogradova (8908772), John Wai (1503217), Tao Wang (12008), Ingrid E. Wertz (11113409), Jonathan R. White (11113412), Siew Kuen Yeap (1346391), Amy Young (251900), Birong Zhang (1947472), Xiaoping Zheng (566379), Wei Zhou (24328), Yu Zhong (291917), Xiaojing Wang (147040)

مصطلحات موضوعية: Cell Biology, Genetics, Neuroscience, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, Exceptional Preclinical Profile, dose, Bioavailable, human, candidate, combination, liability, Phase, Orally, antagonist, Breast Cancer Breast cancer, wild-type ER α tumor model, GDC -9545, estrogen receptor degrader, antiproliferation, SERD, interaction, Estrogen Receptor Antagonist, giredestrant, Fine-tuning, PDX

Relation: https://figshare.com/articles/journal_contribution/GDC-9545_Giredestrant_A_Potent_and_Orally_Bioavailable_Selective_Estrogen_Receptor_Antagonist_and_Degrader_with_an_Exceptional_Preclinical_Profile_for_ER_Breast_Cancer/14959973

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00847.s001

المؤلفون: Jun Liang (251318), Jason R. Zbieg (1892965), Robert A. Blake (8974823), Jae H. Chang (1429789), Stephen Daly (2430460), Antonio G. DiPasquale (1274730), Lori S. Friedman (166879), Thomas Gelzleichter (11113391), Matthew Gill (589302), Jennifer M. Giltnane (11113394), Simon Goodacre (1577413), Jane Guan (166826), Steven J. Hartman (10157036), Ellen Rei Ingalla (8908757), Lorn Kategaya (11113397), James R. Kiefer (1443889), Tracy Kleinheinz (1845637), Sharada S. Labadie (1833826), Tommy Lai (2572615), Jun Li (6494), Jiangpeng Liao (1947631), Zhiguo Liu (594653), Vidhi Mody (8908760), Neville McLean (2128303), Ciara Metcalfe (8908763), Michelle A. Nannini (11113400), Jason Oeh (1845505), Martin G. O’Rourke (11113403), Daniel F. Ortwine (1600621), Yingqing Ran (2100610), Nicholas C. Ray (3064926), Fabien Roussel (3030714), Amy Sambrone (1551289), Deepak Sampath (640340), Leah K. Schutt (11113406), Maia Vinogradova (8908772), John Wai (1503217), Tao Wang (12008), Ingrid E. Wertz (11113409), Jonathan R. White (11113412), Siew Kuen Yeap (1346391), Amy Young (251900), Birong Zhang (1947472), Xiaoping Zheng (566379), Wei Zhou (24328), Yu Zhong (291917), Xiaojing Wang (147040)

مصطلحات موضوعية: Cell Biology, Genetics, Neuroscience, Pharmacology, Biotechnology, Cancer, Infectious Diseases, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, Exceptional Preclinical Profile, dose, Bioavailable, human, candidate, combination, liability, Phase, Orally, antagonist, Breast Cancer Breast cancer, wild-type ER α tumor model, GDC -9545, estrogen receptor degrader, antiproliferation, SERD, interaction, Estrogen Receptor Antagonist, giredestrant, Fine-tuning, PDX

Relation: https://figshare.com/articles/dataset/GDC-9545_Giredestrant_A_Potent_and_Orally_Bioavailable_Selective_Estrogen_Receptor_Antagonist_and_Degrader_with_an_Exceptional_Preclinical_Profile_for_ER_Breast_Cancer/14959976

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00847.s002